Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

(2015) Kathryn G. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia

(2014) A. V. Moorman et al.   BLOOD

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol

(2014) Katharine Patrick et al.   BRITISH JOURNAL OF HAEMATOLOGY

IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome

(2014) Lisa J. Russell et al.   JOURNAL OF CLINICAL ONCOLOGY

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

(2014) Ajay Vora et al.   LANCET ONCOLOGY

Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol

(2013) Nina Toft et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

(2013) E Clappier et al.   LEUKEMIA

Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis

(2012) Ron Ram et al.   AMERICAN JOURNAL OF HEMATOLOGY

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

(2012) Michael J. Burke et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

(2012) C.-H. Pui et al.   BLOOD

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

(2012) N. Gokbuget et al.   BLOOD

The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia

(2012) Anthony V. Moorman   BLOOD REVIEWS

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

(2012) Kathryn G. Roberts et al.   CANCER CELL

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

(2012) Andrea Biondi et al.   LANCET ONCOLOGY

Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia

(2010) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

(2010) Anthony V Moorman et al.   LANCET ONCOLOGY

Treatment non-adherence in teenage and young adult patients with cancer

(2010) Helena J Kondryn et al.   LANCET ONCOLOGY

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993

(2009) Adele K. Fielding et al.   BLOOD

Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group

(2009) James B. Nachman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

(2008) W. Stock et al.   BLOOD

Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group

(2008) L Fern et al.   BRITISH JOURNAL OF CANCER

Acute lymphoblastic leukemia in adolescents and young adults in Finland

(2008) A. Usvasalo et al.   HAEMATOLOGICA

Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

(2008) Josep-María Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia

(2008) T Flohr et al.   LEUKEMIA